These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

703 related articles for article (PubMed ID: 35132063)

  • 1. Emerging new therapeutic antibody derivatives for cancer treatment.
    Jin S; Sun Y; Liang X; Gu X; Ning J; Xu Y; Chen S; Pan L
    Signal Transduct Target Ther; 2022 Feb; 7(1):39. PubMed ID: 35132063
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bispecific Antibodies and Antibody-Drug Conjugates for Cancer Therapy: Technological Considerations.
    Shim H
    Biomolecules; 2020 Feb; 10(3):. PubMed ID: 32111076
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibody treatment in multiple myeloma.
    Maples KT; Johnson C; Lonial S
    Clin Adv Hematol Oncol; 2021 Mar; 19(3):166-174. PubMed ID: 33739965
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bringing Together the Power of T Cell Receptor Mimic and Bispecific Antibodies for Cancer Immunotherapy: Still a Long Way to Go.
    Shivarov V; Blazhev G
    Monoclon Antib Immunodiagn Immunother; 2021 Apr; 40(2):81-85. PubMed ID: 33900820
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Principles and Current Clinical Landscape of Multispecific Antibodies against Cancer.
    Elshiaty M; Schindler H; Christopoulos P
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34073188
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bispecific Antibody (bsAb) Construct Formats and their Application in Cancer Therapy.
    Acheampong DO
    Protein Pept Lett; 2019; 26(7):479-493. PubMed ID: 30864494
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cancer therapy with antibodies.
    Paul S; Konig MF; Pardoll DM; Bettegowda C; Papadopoulos N; Wright KM; Gabelli SB; Ho M; van Elsas A; Zhou S
    Nat Rev Cancer; 2024 Jun; 24(6):399-426. PubMed ID: 38740967
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Precision medicine in clinical oncology: the journey from IgG antibody to IgE.
    Fazekas-Singer J; Singer J; Jensen-Jarolim E
    Curr Opin Allergy Clin Immunol; 2020 Jun; 20(3):282-289. PubMed ID: 32349107
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibody-drug conjugates and bispecific antibodies targeting cancers: applications of click chemistry.
    Hong Y; Nam SM; Moon A
    Arch Pharm Res; 2023 Mar; 46(3):131-148. PubMed ID: 36877356
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bispecific antibody based therapeutics: Strengths and challenges.
    Thakur A; Huang M; Lum LG
    Blood Rev; 2018 Jul; 32(4):339-347. PubMed ID: 29482895
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Unlocking the potential of bispecific ADCs for targeted cancer therapy.
    Zeng H; Ning W; Liu X; Luo W; Xia N
    Front Med; 2024 Aug; 18(4):597-621. PubMed ID: 39039315
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advances in Antibody-Drug Conjugate Design: Current Clinical Landscape and Future Innovations.
    Gauzy-Lazo L; Sassoon I; Brun MP
    SLAS Discov; 2020 Sep; 25(8):843-868. PubMed ID: 32192384
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monoclonal Antibodies, Bispecific Antibodies and Antibody-Drug Conjugates in Oncohematology.
    Mihăilă RG
    Recent Pat Anticancer Drug Discov; 2020; 15(4):272-292. PubMed ID: 32981510
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved cancer therapy and molecular imaging with multivalent, multispecific antibodies.
    Sharkey RM; Rossi EA; Chang CH; Goldenberg DM
    Cancer Biother Radiopharm; 2010 Feb; 25(1):1-12. PubMed ID: 20187791
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunocytokines and bispecific antibodies: two complementary strategies for the selective activation of immune cells at the tumor site.
    Kiefer JD; Neri D
    Immunol Rev; 2016 Mar; 270(1):178-92. PubMed ID: 26864112
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD123 bi-specific antibodies in development in AML: What do we know so far?
    Slade MJ; Uy GL
    Best Pract Res Clin Haematol; 2020 Dec; 33(4):101219. PubMed ID: 33279175
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic/pharmacodynamic relationship of therapeutic monoclonal antibodies used in oncology: Part 1, monoclonal antibodies, antibody-drug conjugates and bispecific T-cell engagers.
    Paci A; Desnoyer A; Delahousse J; Blondel L; Maritaz C; Chaput N; Mir O; Broutin S
    Eur J Cancer; 2020 Mar; 128():107-118. PubMed ID: 32037061
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bispecific monoclonal antibodies for targeted immunotherapy of solid tumors: Recent advances and clinical trials.
    Hosseini SS; Khalili S; Baradaran B; Bidar N; Shahbazi MA; Mosafer J; Hashemzaei M; Mokhtarzadeh A; Hamblin MR
    Int J Biol Macromol; 2021 Jan; 167():1030-1047. PubMed ID: 33197478
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Coming-of-Age of Antibodies in Cancer Therapeutics.
    Ayyar BV; Arora S; O'Kennedy R
    Trends Pharmacol Sci; 2016 Dec; 37(12):1009-1028. PubMed ID: 27745709
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current landscape and future directions of bispecific antibodies in cancer immunotherapy.
    Wei J; Yang Y; Wang G; Liu M
    Front Immunol; 2022; 13():1035276. PubMed ID: 36389699
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.